Source:http://linkedlifedata.com/resource/pubmed/id/18723492
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2008-8-25
|
| pubmed:abstractText |
Pancreatic adenocarcinoma confers one of the highest mortality rates in malignant human tumors with very poor prognosis. Because as yet no treatments are available that produce a substantial survival benefit for this fatal neoplasia, new therapeutic concepts are urgently required to support cancer standard treatment. In search of tumor-associated gangliosides with therapeutic background, we probed a random collection of cancerous and adjacent normal postoperative tissue samples from 38 patients for the expression of CD75s- and iso-CD75s-gangliosides. We exhaustively analyzed the expression of CD75s-1-ganglioside (IV(6)Neu5Ac-nLc4Cer) and structurally closely related iso-CD75s-1-ganglioside (IV(3)Neu5Ac-nLc4Cer) by means of immunohistology of cryosections and semiquantitative TLC of tissue lipid extracts combined with mass spectrometry. CD75s-1- and iso-CD75s-1-ganglioside showed an elevated expression in 42% and 66% of the tumors, respectively, indicating a significant association with neoplastic transformation (P = 0.001). Thus, increased expression of CD75s-1- and iso-CD75s-1-gangliosides renders these cell surface molecules promising candidates for oncologic applications. Further statistical analysis revealed a significant enhancement of CD75s-1-ganglioside in the group of less differentiated tumors (grade >2) suggesting this ganglioside as a potential marker for poor differentiation. The CD75s-specific antitumor drug rViscumin, which represents the recombinant counterpart of the ribosome-inactivating lectin viscumin, has successfully passed clinical phase I trials and provides an opportunity for treating pancreatic cancer. Consequently, if an enhanced expression is existent in malignant tissues, we propose the targeting of CD75s-gangliosides with rViscumin as a novel potential strategy in adjuvant treatment of pancreatic malignancies.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Gangliosides,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Ribosome Inactivating Proteins...,
http://linkedlifedata.com/resource/pubmed/chemical/ST6GAL1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Sialyltransferases,
http://linkedlifedata.com/resource/pubmed/chemical/Toxins, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/mistletoe lectin I
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1535-7163
|
| pubmed:author |
pubmed-author:BerkenkampStefanS,
pubmed-author:DenzAxelA,
pubmed-author:DistlerUteU,
pubmed-author:DreisewerdKlausK,
pubmed-author:Drmi?-HofmanIrenaI,
pubmed-author:GrützmannRobertR,
pubmed-author:HülsewigMarcelM,
pubmed-author:HaierJörgJ,
pubmed-author:MüthingJohannesJ,
pubmed-author:Peter-KatalinicJasnaJ,
pubmed-author:PilarskyChristianC,
pubmed-author:SchmidtM AlexanderMA,
pubmed-author:SenningerNorbertN,
pubmed-author:SouadyJamalJ
|
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2464-75
|
| pubmed:meshHeading |
pubmed-meshheading:18723492-Adenocarcinoma,
pubmed-meshheading:18723492-Antibodies, Neoplasm,
pubmed-meshheading:18723492-Antigens, CD,
pubmed-meshheading:18723492-Antineoplastic Agents,
pubmed-meshheading:18723492-Chemotherapy, Adjuvant,
pubmed-meshheading:18723492-Chromatography, Thin Layer,
pubmed-meshheading:18723492-Gangliosides,
pubmed-meshheading:18723492-Humans,
pubmed-meshheading:18723492-Immunohistochemistry,
pubmed-meshheading:18723492-Microscopy, Fluorescence,
pubmed-meshheading:18723492-Pancreatic Neoplasms,
pubmed-meshheading:18723492-Recombinant Proteins,
pubmed-meshheading:18723492-Ribosome Inactivating Proteins, Type 2,
pubmed-meshheading:18723492-Sialyltransferases,
pubmed-meshheading:18723492-Spectrometry, Mass, Matrix-Assisted Laser...,
pubmed-meshheading:18723492-Toxins, Biological,
pubmed-meshheading:18723492-Tumor Markers, Biological
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer.
|
| pubmed:affiliation |
Institute for Medical Physics and Biophysics, University of Münster, Robert-Koch-Strasse 31, Münster, Germany.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|